{"links":{"feed":"https://www.erudio.com/reports/starlite-2-nct05239533/feed.json","html":"https://www.erudio.com/reports/starlite-2-nct05239533","json":"https://www.erudio.com/reports/starlite-2-nct05239533.json","markdown":"https://www.erudio.com/reports/starlite-2-nct05239533.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"starlite-2-nct05239533"}},"request":"https://www.erudio.com/contact?report=starlite-2-nct05239533"},"offer":{"cited_clinicians":1,"cited_commentary_sources":3,"verified_hcp_statements":2,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":1},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=starlite-2-nct05239533","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=starlite-2-nct05239533","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/starlite-2-nct05239533","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 2 verified statements · 2 from 1 confirmed clinician","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-21T13:43:32.798504Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":2,"no_commentary_found":5},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Maximal tolerated dose (MTD) of 177Lu-girentuximab"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Overall Response Rate/ORR"},{"claim_count":1,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":0,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":2,"coverage":"discussed","id":"A1","source_count":3,"title":"CAIX targeting versus bone-seeking radioligands: indirect rationale from RADICAL/A031801"}],"counts":{"cited_clinicians":1,"cited_clinicians_by_role":{"physician, Medical oncology":1},"cited_physicians":1,"cited_sources":3,"claims_by_expression_type":{"comparison":1,"restatement":1},"claims_by_kind":{"source_observation":2},"clinician_statements":2,"evidence_units":5,"findings":2,"people_cited":1,"people_identity_verified":1,"people_total":1,"screened_sources":15,"verified_claims":2},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":1,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":0},"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"RCC bone metastases: why a clinician considers CAIX-targeted therapy still in trials","title_holders":{"cited_claim_ids":["claim-a34e62c74515870d209e"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 3 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F2","structure":{"claims":2,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":0},"limitations":3,"links":{"context":0,"support":6},"ma_question":false,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"RCC bone metastases: why a clinician questions whether bone-seeking therapy is enough","title_holders":{"cited_claim_ids":["claim-a34e62c74515870d209e"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 3 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"}],"open_question":{"basis":"From findings F1 (1 statement from 1 speaker in 3 sources) and F2 (2 statements from 1 speaker in 3 sources)","cited_claim_ids":["claim-a34e62c74515870d209e","claim-91a1526bb00a4d6d7115"],"finding_ids":["F1","F2"],"question":"What do clinicians need to see from STARLITE-2 to judge the role of CAIX-targeted 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma with bone metastases?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One X account cites STARLITE-2 within a tentative case for CAIX targeting"},{"id":"section-2","level":2,"title":"Beyond the trial population"},{"id":"section-3","level":3,"title":"One X account links its targeting hypothesis to relayed RADICAL/A031801 findings"},{"id":"section-4","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, sequential, phase2","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Maximal tolerated dose (MTD) of 177Lu-girentuximab"},{"findings":[],"id":"T2","label":"Primary endpoint: Overall Response Rate/ORR"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[],"id":"T4","label":"The comparison"},{"findings":[],"id":"T5","label":"Safety and tolerability"},{"findings":[],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-21T13:43:32.798504Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-21T14:04:27Z","record_hash":"a3ea7e25c4783f85a63c7c8b06e19460021820e277e2f10c63de8d7d17486a86","release_hash":"1de2e443d7f357376360843005f64715dda4b667e44d8f3009a7912ccc10ed4a","report_id":"erudio-nct05239533","run_id":"15bb3ec8-b44b-4d80-9919-7f3e9e245712","schema_version":"5.0","slug":"starlite-2-nct05239533","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A medical oncologist’s tentative interest in STARLITE-2 rests on a broader rationale for CAIX targeting, informed by RADICAL/A031801’s reported lack of symptomatic skeletal-event–free survival improvement with radium-223 added to cabozantinib. Their trial-specific discussion is limited to grouping it with STARLITE-1 and LUTEON, leaving this combination’s benefit, safety and treatment role unassessed.","examples":[],"meta_description":"15 sources screened · 2 verified statements (2 from clinicians verified by NPI or staff page) from 3 sources · 2 findings. Updated Nov 21, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-21T14:04:27Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-21T15:17:51Z","kind":"routine","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":15},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a remark on presentation attribution for combined immunotherapy and targeted radioligand treatment in advanced clear-cell renal cell carcinoma.","11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 39 sources about other trials or topics are not included.","All substantive commentary supporting the findings comes from one author repeating the same text in three posts; it does not establish consensus or independent corroboration.","The account groups several studies and treatment combinations together, leaving STARLITE-2-specific benefit, harms, patient selection and implementation unassessed.","Comments that do not use the trial identifier or recorded study names, including wording and transcription variants, may be missing. The report is not a comprehensive account of public HCP discussion.","An additional potentially relevant discussion is not represented because attribution of the presentations it relayed was incomplete; distinct views from that discussion may therefore be missing.","No protocol was listed in the ClinicalTrials.gov material reviewed, and no publication for NCT05239533 or exact regulatory label for 177Lu-labeled-girentuximab was identified. These gaps limit independent clinical and regulatory contextualization of the account’s view."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":3,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":3},"count":3,"evidence_window":{"end":"2026-05-29","start":"2026-05-29"},"retrieval_snapshot":"2026-11-21T13:17:03.821631Z","timeline":[{"count":3,"week":"2026-W22"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT05239533:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05239533:context","quote_policy":"short_quote_link_out"},{"id":"openfda:f570b9c4-6846-4de2-abfa-4d0a4ae4e394:20260812","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7310321803346771968","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1523931257054568450:0a812685-96ec-404b-ae83-c12df9e65c8e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1627088137393692673:ebccbd4d-9e2c-4a63-8c32-00ab4522ccf8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1631610508712325122:7027a98f-e476-4372-9760-f69f9c13df58","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1679584279972462592:3f2f2aa4-4e53-4b19-bfd6-80e4db0c151d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1864674839417553393:79b91d4e-4ed6-4459-a1fa-67681a6dda74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890783619440074942:0831ebce-908f-407f-a079-b906f166ceab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890810132931785162:294884b3-32bb-41d0-b4a3-01f5c11eedb8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890825383802548612:a7eebddf-5f5a-4d6b-92e1-f687247022fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1989497395105955911:4d53ad29-a23b-4036-9233-6bf2f8a1abc0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060455711314948541:d8d4652c-0aa1-44ac-a2c2-2abdbe519eb2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060456591116096003:040dc751-9eac-48a2-aeb0-c0c5f3a26240","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060456794602807485:1f84ef19-b043-4286-9338-a6f487a053b5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080710173879152934:f595b5d7-90b5-4386-a278-821197277d75","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114628293894734243:6d4455bf-6235-474b-8d3d-e4b45e720d05","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":14,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":15},"count":15,"evidence_window":{"end":"2026-10-26","start":"2022-05-10"},"retrieval_snapshot":"2026-11-21T13:17:04.052599Z","timeline":[{"count":1,"week":"2022-W19"},{"count":1,"week":"2023-W07"},{"count":1,"week":"2023-W09"},{"count":1,"week":"2023-W28"},{"count":1,"week":"2024-W49"},{"count":3,"week":"2025-W07"},{"count":1,"week":"2025-W13"},{"count":1,"week":"2025-W46"},{"count":3,"week":"2026-W22"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W44"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":2,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"177Lu-girentuximab","slug":"lutetium-lu-177-girentuximab"},{"brand_names":["Opdivo"],"label":"nivolumab","slug":"nivolumab"}],"indications":[{"reason":"Unmapped registry condition: Clear Cell Renal Cell Carcinoma","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Renal cell carcinoma","slug":"renal-cell-carcinoma"},{"reason":"Unmapped registry condition: Advanced Renal Cell Carcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"STARLITE-2","aliases":["STARLITE-2","Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer","A Phase 2 Open-label Study of Nivolumab Combined With Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients With Clear Cell Advanced Renal Cell Carcinoma"],"brief_title":"Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Clear Cell Renal Cell Carcinoma","Kidney Cancer","Advanced Renal Cell Carcinoma"],"display_condition":"advanced clear cell renal cell carcinoma","display_interventions":[["177Lu-girentuximab","nivolumab"]],"enrollment":{"count":9,"type":"ACTUAL"},"interventions":[{"name":"177Lu-labeled-girentuximab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Nivolumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"89Zr-girentuximab PET/CT","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DIAGNOSTIC_TEST"},{"name":"177Lu whole body (WB) planar and SPECT/CT scans","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DIAGNOSTIC_TEST"}],"nct_id":"NCT05239533","official_title":"A Phase 2 Open-label Study of Nivolumab Combined With Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients With Clear Cell Advanced Renal Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2027-03","type":"ESTIMATED"},"primary_endpoints":[{"description":"To determine the maximal tolerated dose (MTD) of 177Lu-girentuximab when given in combination with nivolumab (safety lead-in)","measure":"Maximal tolerated dose (MTD) of 177Lu-girentuximab","timeFrame":"24 (+/- 2) weeks"},{"description":"efficacy of the combination at the MTD of 177Lu-labelled girentuximab in patients with advanced ccRCC as assessed by best ORR by 24 (+/- 2) weeks by Response Evaluation Criteria In Solid Tumors (RECIST v1.1).","measure":"Overall Response Rate/ORR","timeFrame":"24 (+/- 2) weeks"}],"registered_date":{"date":"2022-02-15","type":"ACTUAL"},"registry_last_updated":"2026-01-14","registry_url":"https://clinicaltrials.gov/study/NCT05239533","short_name":"STARLITE-2","short_name_basis":"canonical_name","sponsor":"Memorial Sloan Kettering Cancer Center","start_date":{"date":"2022-02-16","type":"ACTUAL"},"study_design":"interventional, randomized, sequential, phase2","study_ids":[{"id":"21-328","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}